A failure of cetuximab to downregulate EphA2 expression in NRAS-mutant CRC cells, in comparison with cetuximab-responsive CRC cells, was suggested as a potential contributor to resistance to this drug [281]. This evidence concerns the gene EPHA2 and colorectal carcinoma.